Toripalimab and Chemotherapy for Bladder Cancer
Author Information
Author(s): Ning Wei, Chang Pengkang, Zheng Ji, Chen Wei
Primary Institution: Third Military Medical University (Army Medical University), Chongqing, China
Hypothesis
Can toripalimab combined with chemotherapy improve outcomes for patients with metastatic muscle-invasive bladder cancer?
Conclusion
The combination of radical cystectomy, adjuvant chemotherapy with toripalimab, and maintenance therapy with toripalimab may be a promising treatment for metastatic muscle-invasive bladder cancer.
Supporting Evidence
- The patient exhibited promising progression-free survival and safety after treatment.
- High tumor proportion score of PD-L1 expression may predict immunotherapy efficacy.
- Next-generation sequencing revealed mutations in CDKN2A and TP53.
Takeaway
One patient with advanced bladder cancer received a new treatment combining surgery, chemotherapy, and immunotherapy, which helped improve his health.
Methodology
The patient underwent radical cystectomy followed by adjuvant therapy with toripalimab and chemotherapy, and then maintenance therapy with toripalimab.
Limitations
The study is based on a single case report, limiting the generalizability of the findings.
Participant Demographics
An 85-year-old male patient with a history of type 2 diabetes and chronic bronchitis.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website